Sugi Predict

Sugi Predict / Targets / TAAR1

TAAR1

Trace amine-associated receptor 1 · Q96RJ0 · TAAR1 on Sugi Atlas →

264,303 patent compounds predicted against TAAR1, 148,468 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9243 SCHEMBL9243 1.00 11/20
Biphenyl Biphenyl (SCHEMBL30337) 0.52 11/20
SCHEMBL5414 SCHEMBL5414 1.00 10/20
SCHEMBL6081 SCHEMBL6081 1.00 10/20
SCHEMBL43719 SCHEMBL43719 1.00 10/20
SCHEMBL37363 SCHEMBL37363 0.55 10/20
Tyramine Tyramine (SCHEMBL4111) 1.00 9/20
SCHEMBL4920 SCHEMBL4920 1.00 9/20
SCHEMBL44414 SCHEMBL44414 0.63 9/20
SCHEMBL8542 SCHEMBL8542 0.41 9/20
Naphazoline Naphazoline (SCHEMBL24153) 1.00 8/20
Naphazoline Naphazoline (SCHEMBL34532) 1.00 8/20
Tyramine Tyramine (SCHEMBL2121) 0.95 8/20
SCHEMBL44646 SCHEMBL44646 0.62 8/20
SCHEMBL30600 SCHEMBL30600 0.40 8/20
SCHEMBL1878 SCHEMBL1878 1.00 7/20
SCHEMBL40017 SCHEMBL40017 1.00 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL44146) 0.60 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL25973) 0.50 7/20
SCHEMBL15247 SCHEMBL15247 0.46 7/20

Clinical trials — most relevant to TAAR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration PHASE4COMPLETED
Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake PHASE4COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep PHASE3COMPLETED
Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD). PHASE3COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone PHASE2COMPLETED
Varenicline (Chantix™) for the Treatment of Alcohol Dependence PHASE2COMPLETED
Brexpiprazole in Alcohol Use Disorder PHASE2RECRUITING
Genetic Effects on Dopamine Response to an Opiate PHASE2COMPLETED
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder PHASE2COMPLETED
Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency PHASE2COMPLETED
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder PHASE1RECRUITING
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) PHASE1RECRUITING
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides PHASE1COMPLETED
Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa nanCOMPLETED
The Genetic Basis for Vulnerability to Substance Abuse nanCOMPLETED
Dopamine Receptor Imaging in Mood Disorders nanCOMPLETED
Serotonin Transporters in Alcoholism nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome nanUNKNOWN
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA) nanACTIVE_NOT_RECRUITING
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers. nanUNKNOWN
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. nanUNKNOWN
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED
Dopamine and Insulin Resistance nanCOMPLETED
Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study nanCOMPLETED
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a TAAR1 binder may also engage these)

ProteinNameSimilarity
Q5QD29 — 1.000 Q5QD29 →
Q8HZ64 — 1.000 Q8HZ64 →
Q5QD16 — 1.000 Q5QD16 →
Q5QNP2 — 0.998 Q5QNP2 →
Q9P1P5 — 0.995 Q9P1P5 →
Q5QD24 — 0.994 Q5QD24 →
Q923Y7 — 0.993 Q923Y7 →
Q5QD15 — 0.992 Q5QD15 →
Q923Y9 — 0.991 Q923Y9 →
Q9P1P4 — 0.989 Q9P1P4 →
Q923Y8 — 0.987 Q923Y8 →
Q5QD25 — 0.986 Q5QD25 →
Q923X9 — 0.986 Q923X9 →
Q5QD17 — 0.984 Q5QD17 →
Q5QD12 — 0.984 Q5QD12 →
Q5QD28 — 0.982 Q5QD28 →
Q5QD06 — 0.982 Q5QD06 →
Q923X6 — 0.981 Q923X6 →
Q5QD08 — 0.980 Q5QD08 →
Q96RI8 — 0.979 Q96RI8 →
Q923X5 — 0.979 Q923X5 →
Q5QD23 — 0.978 Q5QD23 →
Q923Y0 — 0.978 Q923Y0 →
Q5QD13 — 0.978 Q5QD13 →
Q5QD21 — 0.977 Q5QD21 →
Q923Y4 — 0.977 Q923Y4 →
TAAR5 Trace amine-associated receptor 5 0.977 landscape →
Q5QD05 — 0.977 Q5QD05 →
Q5W8W0 — 0.977 Q5W8W0 →
Q923Y2 — 0.976 Q923Y2 →